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Abstract
Epitopes are a hallmark of the antigen specific immune response. The identification and
characterization of epitopes is essential for modern immunologic studies, from investigating
cellular responses against tumors to understanding host/pathogen interactions especially in the
case of bacteria with intracellular residence. Here, we have utilized a novel approach to identify T
cell epitopes exploiting the exquisite ability of particulate antigens, in the form of beads, to deliver
exogenous antigen to both MHC class I and class II pathways for presentation to T cell
hybridomas. In the current study, we coupled this functional assay with two distinct protein
expression libraries to develop a methodology for the characterization of T cell epitopes. One set
of expression libraries containing single amino acid substitutions in a defined epitope sequence
was interrogated to identify epitopes with enhanced T cell stimulation for a MHC class I epitope.
The second expression library is comprised of the majority of open reading frames from the
intracellular pathogen and potential biowarfare agent, Francisella tularensis. By automating
aspects of this technology, we have been able to functionally screen and identify novel T cell
epitopes within F. tularensis. We have also expanded upon these studies to generate a novel
expression vector that enables immunization of recombinant protein into mice, which has been
utilized to facilitate T cell epitope discovery for proteins that are critically linked to Francisella
pathogenicity. This methodology should be applicable to a variety of systems and other pathogens.
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1. Introduction
The identification and characterization of T cell epitopes has become essential for modern
immunologic studies. Once identified, T cell epitopes can be used to monitor T cell
responses using ELI-spot analyses or by flow cytometry analyses employing intracellular
cytokine staining or MHC tetramer analyses (Altman et al., 1996; Chapman et al., 2002;
McGavern et al., 2002; Kern et al., 2005). These techniques allowed investigators to
characterize antigen specific T cells arising in response to a variety of pathogens as well as
in anti-tumor responses (Ogg et al., 1998; He et al., 1999; Lee et al., 1999; McSorley et al.,
2002; Stetson et al., 2002). Furthermore, the epitopes themselves can also be used in
developing vaccines aimed at enhancing T cell responses (Pogue et al., 1995; Abdel-Motal
et al., 2001; Kessler and Melief, 2007; Depla et al., 2008; Gregory et al., 2009).
Due to their importance and utility in immunology, a variety of functional and biochemical
approaches have been developed to identify peptide epitopes (Hunt et al., 1992; Anthony
and Lehmann, 2003; Koelle, 2003; Lemmel and Stevanovic, 2003; Sospedra et al., 2003;
Wang, 2003; Buus and Claesson, 2004; Gunawardana and Diamandis, 2007; Kessler and
Melief, 2007; Richards et al., 2010). The identification of peptide epitopes coupled with the
development of large scale MHC peptide binding assays, has led to the development of in
silico peptide binding algorithms and epitopes database tools for predicting MHC class I and
class II epitopes (Bian et al., 2003; Martin et al., 2003; Peters et al., 2005). As information
about epitopes has become available, it has been used to enhance responses to defined
epitopes by increasing their binding to their respective MHC molecules (Pogue et al., 1995;
Overwijk et al., 1998; Katsara et al., 2008). Further, as sequence information has become
available for pathogens, attempts have been made to identify potential T cell epitopes in
these pathogenic organisms (Doolan et al., 2003a; Doolan et al., 2003b; Gregory et al.,
2009; Moise et al., 2009; Walsh et al., 2009; Alexander et al., 2010). Importantly the
increasing amount of available sequence information, coupled with the recent advances in
molecular biology and genomics, has enabled the construction of extensive expression
libraries of defined proteins. These libraries offer new opportunities for a variety of
innovative studies including the definition and characterization of B cell and T cell epitopes
(Davies et al., 2008; Eyles et al., 2008; Valentino and Frelinger, 2009).
In the current study, we report the development of a method to screen expression libraries to
define and characterize T cell epitopes. We have previously developed an approach
employing the highly efficient processing of solid phase antigen delivery using antigen
coupled to beads in conjunction with a functional assay to identify T cell epitopes in specific
proteins (Turner et al., 2001; Valentino et al., 2009). An important feature of this assay is the
use of a functional readout employing a T cell hybridoma that has been generated from T
cells arising during an immune reaction, validating the epitope a priori. We reasoned that
this basic method could be coupled with expression libraries to develop a high-throughput
screening methodology for the identification of T cell epitopes. As described in this work,
we have used bacterial expression libraries and the functional T cell screen for two distinct
applications to illustrate its general utility.
In the first approach, we have screened a panel of expression libraries to identify altered
peptide ligands (APL) that affect T cell stimulation. APL are peptides having amino acid
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substitutions that result in either enhanced or attenuated T cell responses compared to the
parental wild-type ligand sequence. Altered peptide ligands are of interest since they are
being used in a variety of contexts, including studies on T cell signaling and differentiation,
autoimmunity, immune responses to tumors and infectious agents, and are also being
investigated for clinical use (Klenerman et al., 1995; Rivoltini et al., 1995; Wang et al.,
1999; Bielekova and Martin, 2001; Fong et al., 2001; Kessels et al., 2001; Aruna et al.,
2006; Tsukamoto et al., 2006; Uhlin et al., 2006; Yu et al., 2008; Sadegh-Nasseri et al.,
2010; Dominguez et al., 2011). In order to identify potential APL, we employed random
mutagenesis methods to generate expression libraries of mutated T cell epitopes that could
then be functionally screened to identify those with super-agonist properties. This
mutagenesis approach, coupled with a functional screen, should allow one to identify
improved epitopes without prior knowledge of which substitutions might result in enhanced
recognition by T cells. As proof of principle of this approach to identify altered peptide
ligands (APL), we used a T cell hybridoma which recognizes a previously described MHC
class I restricted epitope of Prostate Specific Antigen (PSA 188 – 197) called HL10 (Turner
et al., 2001) to screen a collection of 10 expression libraries we have constructed encoding
variants of this epitope.
In the second approach using expression libraries, we have taken advantage of the
availability of annotated genomic DNA libraries of pathogens determined by whole genome
sequencing. From an available Gateway donor clone library, we constructed a bacterial
expression library consisting of nearly all the open reading frames of Francisella tularensis
strain SchuS4 (http://www.beiresources.org, 2011; http://www.jvci.org, 2011), chosen
because T cells are important effectors in the response to this facultative intracellular
pathogen (Elkins et al., 2007; Cowley and Elkins, 2011). Here we illustrate the feasibility of
using an ordered array of Francisella tularensis genes to produce a library of recombinant
proteins that can be screened for T cell epitopes. We further extend these studies by
generating a new expression vector so that selected genes could be expressed and used for
immunization studies. We have used this vector to express several proteins found within the
Francisella pathogenicity island, that were used to immunize mice, generate T cell
hybridomas, and identify T cell epitopes within the intracellular growth locus encoded
proteins IglC and IglB.
2. Methods and Materials
2.1 Generation and screening of the HL10 mutant collection
The APL expression libraries were generated using oligonucleotides to mutagenize a class I
epitope (HL10) from the wild type PSA sequence to the altered epitopes. These
oligonucleotides included several features. Oligonucleotides were randomized at specific
sequential positions to introduce mutations into the PSA 188 – 197 epitope (HL10). An
example sequence of the epitope region of an oligonucleotide used to generate one of the ten
positional mutant libraries was as follows: NNN CCT CAG AAG GTG ACC AAG TTC
ATG CTG TAG A where NNN denotes the randomized codon at position 1 (P1) with the
remaining encoding wild type HL10 epitope sequence. In addition, sequence corresponding
to a 5 amino acid linker from wild type PSA was included immediately upstream of the
mutagenic region to facilitate natural processing and presentation. Finally, to faciliate
cloning the oligonucleotides included sequences that generate KpnI and HindIII compatible
ends after annealing. The oligonucleotides were annealed to complimentary strands, ligated
into the expression vector pQE40 (Qiagen, Valencia, CA) via KpnI and HindIII restriction
sites, and verified by sequencing (ACGT, Northbrook, IL). The HL10 mutants are expressed
as the COOH-terminal portion of a fusion protein along with (5′-3′) a 6x Histidine tag (6x
His), Dihydrofolate reductase (DHFR), and a fragment of ovalbumin (OVA 255 – 345). The
6x-His tag facilitates the purification of the recombinant protein, DHFR allows for stable
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protein expression, and the ovalbumin fragment contains a H2Kb restricted CTL epitope
which allowed us to confirm protein expression using a T cell hybrid that is specific for the
ovalbumin fragment (data not shown).
Approximately ninety mutant clones were used to generate each positional library of HL10.
Six wells were left available for in-plate controls for each experiment. Individual bacterial
colonies containing single mutant constructs were used to inoculate 100μl Luria Broth in 96-
well plates and grown overnight at 37°C. Each plate was duplicated to a 96-well plate
containing 70% glycerol and frozen, which served as the master library. Protein expression
in E. coli was induced using 1mM IPTG. The bacterial cells were harvested by
centrifugation, lysed with 8M urea (pH 7.0) for 2 hours at room temperature. Following an
additional centrifugation, supernatants were isolated as clarified lysates. An aliquot of each
lysate (20 μl) was added to PBS (80 μl) in 96-well polycarbonate plates, and tosyl-activated
beads (Invitrogen, Carlsbad, CA) at a concentration of 2 × 109 beads/ml were added to the
diluted lysates and incubated for 16 hours at 37°C. The beads were washed and added to
tissue culture treated 96-well flat bottom plates containing 1 × 105 cells of the antigen
presenting cell line RAW 264.7 and 2 × 105 the HL10 specific T cell hybrid, PSA-HI
(Turner et al., 2001). The assay proceeded overnight at 37°C. Activation of PSA-HI
hybridoma was detected using the β-galactosidase substrate X-gal and enumerating blue
cells (Turner et al., 2001; Valentino et al., 2009; Valentino et al., 2011).
2.2. HL10 mutant library peptides and relative binding assay
The HL10 related peptides were purchased either from Macromolecular Resources (Fort
Collins, CO) or SynPep Corporation (Palo Alto, CA) and are as follows: HL10 W.T.
(HPQKVTKFML), H1A (APQKVTKFML), H1S (SPQKVTKFML), T6P
(HPQKVPKFML), T6S (HPQKVSKFML), K7R (HPQKVTRFML), M9N
(HPQKVTKFNL). Synthetic peptide (20–80 μM) was added to the top well of a tissue
culture treated 96-well plate and titrated using four-fold dilutions in 5% MAT/P media.
Reactivity assay was conducted as described above and β-galactosidase expression was
detected using a soluble substrate, CPRG in Z-buffer, and the color development was
measured at 610 nm.
Relative peptide binding to H2Ld was assessed by measuring the ability to stabilize Ld on
the surface of T2-Ld cells. The cell line T2-Ld is defective in endogenous peptide processing
and thus expresses low levels of unstable H2Ld on its surface (Anderson et al., 1993). The
binding of peptide to this unstable molecule stabilizes its structure, allowing it to be detected
using an anti-H2Ld antibody. Cells were pulsed with 100μM of the appropriate peptide at
25°C for 16 hours in serum-free media. The cells were blocked with 1% goat serum for 1
hour on ice. Cells were then stained with saturating anti-H2Ld antibody (clone 30-5-7S),
which is sensitive to peptide binding, on ice for 2 hours. Cells were then stained with goat-
anti-mouse FITC antibody and analyzed by FACScan® (Becton Dickinson & Co., Mountain
View, CA). Peptide loading to Ld resulted in a proportional increase in mean channel
fluorescence of antibody staining. The results are reported as the ratio of mean channel
fluorescence of mutant and control peptides divided by the mean channel fluorescence of
HL10, after the subtraction of background staining from each.
2.3. Generating the Francisella tularensis SchuS4 expression library
The J. Craig Venter Institute Pathogen Functional Genomics Resource Center (PFGRC) has
made available, an arrayed genomic library containing the majority of ORFs from F.
tularensis SchuS4 in the pDONR221 vector
(http://pfgrc.jcvi.org/index.php/gateway_clones.html, 2011). Briefly, the PFGRC utilized
annotated sequence of F. tularensis SchuS4 to amplify 1645 open reading frames to include
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native start codons, remove stop codons, and include att sites that facilitate recombination
into the Gateway pDONR211 vector. The plasmids were subsequently individually
introduced into E. coli strain DH10B-T1 and the resulting genomic library is comprised of
1645 clones that have been sequence validated and individually arrayed into nineteen 96
well microtiter plates. The expression library clones were generated by shuttling each F.
tularensis gene encoded in the pDONR221 vector into the bacterial expression vector
pBAD-DEST49 using the Gateway Cloning technology (Invitrogen, Carlsbad, CA)
following manufacturers specifications as previously described (Valentino and Frelinger,
2009). Briefly, the expression vector pBAD-DEST49 creates a fusion protein containing the
bacterial protein thioredoxin (THIO) fused in frame with an individual ORF from F.
tularensis SchuS4 followed by V6 and 6x histidine (6x His) coding regions.
Production of expression library thioredoxin fusion protein was performed as previously
described with minor modifications (Valentino and Frelinger, 2009). Recombinant proteins
were isolated by lysing the bacterial pellets with 8M urea (pH8) either with or without
addition of Nonidet P-40 detergent as indicated in the figure legends and purified over Ni-
NTA column (Qiagen, Valencia, CA) in a high-throughput fashion using a BioRobot 3000
(Qiagen, Valencia, CA). Purified protein was coupled to tosylactivated M280 magnetic
Dynabeads (Invitrogen, Carlsbad, CA) as described (Valentino et al., 2009; Valentino et al.,
2011). To examine expression and purification procedures, an aliquot of each purified
protein from all of the library expression plates (20 × 96 well plates) was blotted onto
Hybond C membrane using a 96-well dot blot apparatus (Bio-Rad, Hercules, CA). The
membrane was blocked with 5% non-fat dry milk in TBS-Tween before probing with anti-
thioredoxin antibody (1:5000) for 2 hours at room temperature. The membrane was then
washed 3 times in TBS-Tween before addition of rabbit anti-mouse IgG (Jackson
Immunoresearch, West Grove, PA) conjugated to HRP detection antibody at a 1:5000
dilution for 1 hour at room temperature, followed by washing and detection using the ECL+
chemiluminescent reagent (GE Healthcare Life Sciences, Piscataway, NJ).
2.4. Generation of hybridomas used for screening the Francisella expression library
C57BL/6 (H2b) and BALB/c (H2d) mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). The T cell fusion partner BWZ.36/CD8+, which can be used to make MHC
class II and class I restricted hybridomas, was kindly provided by Dr. Nilabh Shastri and
maintained as previously described (Sanderson and Shastri, 1994). The Tul4 specific
hybridoma FT13 1E4B4 was previously characterized by our lab (Valentino et al., 2009). F.
tularensis Live Vaccine Strain (LVS) was obtained from the CDC in Atlanta, GA.
T cell hybrids that were Francisella specific were produced in two ways as described
previously (Valentino et al., 2009). Briefly, to generate hybridomas from a natural infection,
C57BL/6 or BALB/c mice were inoculated intradermally at the base of the tail with 1 × 105
viable F. tularensis LVS and allowed to rest for 3 weeks to resolve the infection before
harvesting splenocytes (Cowley and Elkins, 2003). For the hybridomas generated with
recombinant protein immunization, C57BL/6 or BALB/c mice were injected in the footpad
with approximately 50μg of recombinant proteins emulsified in complete Freund’s adjuvant,
rested for 3 weeks, and were then boosted once with recombinant proteins emulsified in
incomplete Freund’s adjuvant before harvesting draining popliteal lymph node seven days
later. Following several rounds of in vitro restimulation, the T cell blasts from either natural
infection or recombinant immunization were fused with the BWZ.36/CD8+ fusion partner
containing lacZ driven by the Interleukin-2 promotor element as described (Sanderson and
Shastri, 1994; Turner et al., 2001). Fusions from both approaches were grown in HAT
selection media until clones could be evaluated for activity, measured by using a beta-
galactosidase substrate as previously described (Valentino et al., 2011). While the recovery
of antigen specific hybridomas was very variable, likely depending on the immunization
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efficacy as well as the restimulation procedure, a typical fusion might yield approximately
100 – 150 growing wells, of which 20–50% could be triggered with anti-CD3. Of those
hybridomas, 1–20% appeared to be Francisella specific and these were almost all class II
restricted.
2.5. Antigen screening of SchuS4 library
The antigen screening assay was adapted from the T cell antigen discovery (T-CAD) assay
(Turner et al., 2001). Screening assays were performed by incubating 2×105 hybridomas
with 1×105 irradiated spleen cells as APC in 200μl total volume per well in a 96 well tissue
culture plate. Syngeneic spleen cells were harvested from naïve wild type C57BL/6 or
BALB/c mice. All recombinant proteins used were isolated from bacterial lysates,
conjugated to tosyl-activated beads in either 96 well plates for throughput library screening
or 1.5 ml tubes for deletion mapping as described above, and used at 2×106 beads per well.
The coupling procedure was carried out in 1.2 ml deep 96 well plates to maintain the high-
throughput and arrayed feature of the library. Assays were also performed in the presence of
synthesized peptides listed below at 10μg per peptide and Francisella lysates at 20μg per
well. Additional positive controls for hybridoma viability and functionality that were
included in each screening assay but not shown in figures were Francisella extracts,
produced by killing F. tularensis LVS or SchuS4 in 70% ethanol (Woolard et al., 2007), and
plate bound anti-CD3 antibody (clone 500A2) (BD Pharmingen, San Jose, CA). After 18–24
hour incubation at 37°C, cultures were developed using the beta-galactosidase assay as
described previously (Sanderson and Shastri, 1994; Valentino et al., 2011). For data
analysis, wells with low numbers of activated (< 1000 blue cells) the entire well was
visually counted. In wells with high numbers (>1000 blue cells) four representative fields of
view were counted, averaged, and multiplied by the number of fields per well (Valentino et
al., 2009).
2.6. Deletion construct mapping and Francisella tularensis peptides
Deletion constructs were generated and mapping experiments conducted basically as
described previously (Valentino et al., 2009; Valentino et al., 2011). Briefly, nested
carboxy-terminal deletion constructs were generated in either the pQE40 or pBAD-DEST49
vector. Production of all fusion proteins was performed in Escherichia coli strain M15 as
described by manufacturers specifications (Qiagen, Valencia, CA). Recombinant proteins
were isolated from bacterial lysates by Ni-NTA column purification and coupled to
tosylactivated Dynabeads (Invitrogen, Carlsbad, CA). Deletion construct production and
characterization was confirmed by SDS-PAGE techniques and Coomassie Blue staining as
described previously (data not shown) (Turner et al., 2001).
The refined regions shown by deletion protein mapping to contain an epitope were analyzed
with several peptide prediction algorithms: Rankpep,
http://imed.med.ucm.es/Tools/rankpep.html, 2011; NetMHCII 2.0,
http://www.cbs.dtu.dk/services/NetMHCII-2.0/, 2011; and IEDB Analysis Resource
http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html, 2011. F. tularensis
peptides were synthesized by SynBioSci (Livermore, CA) and are as follows: L3 1 – 21
(MSLGLVGRKCGMTRIFTEDGV), L3 7 21 (GRKCGMTRIFTEDGV), L3 7 (C10S) – 21
(GRKSGMTRIFTEDGV), IglB 472 – 486 (IPGKPGWYSCKINVI), IglB 475 – 489
(KPGWYSCKINVIPHI), IglB 475 – 486 (KPGWYSCKINVI), GroEL 441 – 455
(ALLRKAIEAPLRQIV), IglC 56 – 70 (GEDVTKADSATAAS), IglC 60 – 73
(TKADSATAASVIR), IglC 127 – 143 (QEYKTDEAWGIMIDLSN), IglC 131–147
(DEAWGIMIDLSNLELY), IglC 142 – 157 (SNLELYPISAKAFSISI). The Tul4 86 – 99
(RLQWQAPEGSKCHD) peptide derived from F. tularensis was also synthesized by
SynBioSci (Livermore, CA) (Valentino et al., 2009). OVA 323 – 339 (pOVAII) peptide
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(ISQAVHAAHAEINEAGR) served as irrelevant peptide negative control and was
synthesized by Macro-Molecular Resources (University of Colorado, Ft. Collins, CO). The
B-lymphoblastoid cell line M12 parental expressing I-Ed and I-Ad and M12 lines expressing
only I-Ed (M12.A) or I-Ad (M12.B) were used to ascertain which restriction element
displays the L3 peptide (Qiagen, Valencia, CA).
2.7. Generation of a novel Gateway compatible vector
The Gateway compatible pQE40-DEST expression vector was generated by blunt end
cloning the Gateway Vector Conversion cassette (Invitrogen, Carlsbad, CA), containing
chloramphenicol resistance and ccdB gene flanked by attR recombination sites, into the
SmaI restriction site within the multiple cloning site (MCS) of the pQE40 vector. The
ligation product was transformed into One Shot ccdB survival cells (Invitrogen, Carlsbad,
CA) and transformants were selected on chloramphenicol/ampicillin plates. The pQE40-
DEST vector was validated based upon sequence analysis and verifying correct functionality
in the Gateway cloning system as described by the manufacturer (Invitrogen, Carlsbad, CA).
3. Results & Discussion
3.1. Construction and analysis of the mutant libraries
We sought to develop an approach that could facilitate throughput processing of large
numbers of clones, in an effort to discover altered peptides of a MHC class I restricted
epitope of Prostate Specific Antigen (PSA), called HL10, that were better than the initial
wild type epitope in stimulating a T cell hybridoma. A modified version of the pQE40
vector construct was used to express the altered forms of HL10 epitope. As illustrated in
Figure 1A, the HL10 epitope was expressed in the context of a fusion protein containing a
6x-Histidine tag at the amino-terminus, dihydrofolate reductase (DHFR) to facilitate stable
expression in E. coli., a fragment of the protein ovalbumin (OVA 255–354), which allows
for additional control experiments, and the HL10 epitope preceded by 5 amino acids that
naturally precede HL10 in PSA, to allow for proper processing and loading of HL10 onto
class I MHC molecules.
To introduce mutations into the plasmid encoding HL10, we utilized oligonucleotides that
were randomized at a given codon (Fig. 1B). In this technique we sequentially mutagenized
each codon individually by a saturation mutagenesis technique, and since the epitope
contained 10 amino acids we generated 10 libraries, one for each amino acid. As shown in
Figure 1C, the mutant constructs from each library were then cloned en mass into the pQE40
expression vector and transformed into E.coli. as described in the Materials and Methods
section 2.1. Positional mutant HL10 libraries were generated by picking approximately 90
clones to a 96-well plate for each of the 10 amino acid positions. These 10 individual
positional mutant libraries (P1-P10) are referred to as the HL10 mutant collection. The
library was analyzed for randomness by isolating 72 clones from the position 1 (P1) library
and sequencing the epitopes encoded by the plasmid (data not shown). From this number of
clones, we identified 15 different amino acid substitutions as well as 1 stop codon at position
1. As expected, based on the genetic code, some amino acids are more commonly identified
than others. There may also be some bias over the expected value toward mutations with
more GC content, perhaps because of better base pairing. Nevertheless, this approach clearly
generates a large bank of suitable mutants for screening. Upon validation that the individual
positional libraries could contain assorted mutants, protein expression for the entire HL10
mutant collection was induced and crude lysates from each mutant clone individually
coupled to tosyl activated paramagnetic beads to generate a solid phase antigen to be used in
a T cell hybridoma functional assay, as described in Materials and Methods section 2.1
(Figure 1C). SDS polyacrylamide gel electrophoresis followed by Coomassie staining
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indicated that as expected, similar levels of protein were expressed since the mutant epitopes
were different from one another by only 1 amino acid substitution (data not shown).
By using the random mutagenesis methods discussed above and a functional screen, we
speculated that we could identify improved APL without prior knowledge or preconceived
ideas as to which substitutions might result in enhanced recognition by T cells. The
functional screen was conducted by administering the expressed mutant APLs coupled to
beads to APCs for processing and presentation to the PSA-HI hybridoma, which recognizes
the HL10 epitope in conjunction with the Ld class I molecule. Hybridoma activation was
scored by enumerating the number of β-galactosidase expressing (blue) T cell hybrids in
each well after developing with X-gal substrate, as done previously (Figure 2). Several
clones resulted in dramatically enhanced stimulation as illustrated by the increased number
of activated hybridomas, while most of the clones in the library elicited little or no increase
in the activation of the hybridoma compared to wild type peptide. All of the clones that
appeared to increase the activation of the PSA-HI hybridoma were picked from the master
library, re-screened functionally (data not shown), and the plasmid DNA encoding the
putative mutant epitopes were sequenced to identify amino acid substitutions (see Figure 2).
Several conclusions emerge from these studies. First, there were wide ranges in the degree
of improvement of recognition ranging from 2 fold to more than 70 fold as measured by
activation of the hybridoma. Second, the vast majority of the clones retested positive, and
there were only 2 clones that did not retest positive in a subsequent re-screen. In one case,
DNA sequencing revealed that the putative mutant in the position 3 library was a false
positive, as it encoded the wild type amino acid (see Figure 2 P3 Q(WT)). In another case,
the putative mutant clone in position 4 library (P4 K→V), while indeed encoding a
substitution, failed to result in significant increase above the wild type construct when
retested. Third, the assay was surprisingly quantitative and consistent in that different clones
containing the same amino acid substitution in a given library (compare all the P
substitutions in Figure 2 P6), led to similar increases in PSA-HI hybridoma activation. For
example, the best activators in the position 1 library encoded alanine substitutions, while the
serine mutants were somewhat less stimulatory. Similarly, in the position 6 library, the
serine substitutions were more stimulatory that the proline substitutions (Figure 2). This was
consistently found even in independent mutations encoded by different codons. Taken
together, these results demonstrate that screening large numbers of clones is both feasible
and highly reproducible using the approach described above.
3.2. Analyses using synthetic peptides
Data from the screen strongly suggested that a number of the altered peptides result in
enhanced T cell recognition. However, to obtain more quantitative data and to rigorously
examine this issue, we tested these mutants using synthetic peptides corresponding to each
substitution (Figure 3). This allowed us to compare directly the peptides at varying
concentrations and to determine quantitatively how the altered peptides compared to wild
type HL10 peptide in their ability to activate the PSA-HI hybridoma. When tested, all of the
mutant peptides resulted in significantly better activation of the PSA-HI hybridoma than the
wild type peptide on a molar basis, with the exception of the HL10 mutant F8G which was
included as a negative control peptide in these studies (Figure 3). The strength of the
synthetic peptides generally followed the same pattern as seen in the initial screen using
crude extracts. For example, the histidine to serine substitution at position 1 (H1S) was the
least potent of the identified mutants, while the threonine to serine substitution at position 6
(T6S) was the most potent. Interestingly, the mutants are even more potent when tested
using purified synthetic peptides than what might be expected from the initial screen. For
example, serine substitution at position 6 yields an increase in activity of 10,000 fold as
compared to the wild type peptide based on the concentration of peptide required to reach
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the half-maximal activation level of PSA-HI. These results demonstrate that this screen can
identify enhanced altered peptides of a class I MHC restricted epitope.
3.3. MHC binding ability of the enhanced APL
We wanted to determine the nature of the enhanced APLs. We hypothesized that the APLs
were likely to be one of two classes of substitutions: those that have a higher affinity for the
class I MHC molecule or those that have higher affinity for the T cell receptor of PSA-HI.
As a means of determining the relative ability of the peptides to bind to MHC molecules, we
performed an experiment examining the ability of the peptides to stabilize Ld molecules at
the surface of the TAP-deficient mutant cell line T2-Ld. Because this cell line lacks a
functional TAP transporter system necessary for loading peptides onto class I molecules, the
cells bear low levels of class I molecules on their surface. However, these class I molecules
can be stabilized by exogenous peptides, which results in increased expression that can be
measured by flow cytometry using a monoclonal antibody specific for Ld. In these
experiments, binding was calculated relative to wild type HL10 peptide and expressed as a
ratio, with the level of stabilization of Ld by HL10 being defined as 1. As shown in Figure 4,
using this assay, the peptides H1A and H1S, could be characterized with enhanced binding,
showing a 1.6 and 1.8 fold increase, respectively. Additional studies using a competition
binding assay also indicated that the histidine to alanine mutation increased binding to the
MHC (data not shown). This is consistent with prior studies using a different H2Ld binding
peptide in which an alanine substitution at the first position resulted in better binding than
the wild-type peptide (Slansky et al., 2000). Curation and analysis of peptide binding data
has identified the preferred anchor residues for H2Ld to be a proline at position 2 and either
an asparagine, tryptophan, or tyrosine at position 9 (see Immune Epitope Database and
Analysis Resource at http://www.immuneepitope.org, 2011; and (Vita et al., 2008; Vita et
al., 2010)). Several interesting observations can be made when the binding motif of H2Ld is
compared to the wild type HL10 epitope and the APLs identified by our screen. The wild
type HL10 peptide contains a proline at the P2 position and no position 2 mutant APLs were
identified, reinforcing that position 2 is indeed a major anchor. While the HL10 peptide
contains a methionine residue at position 9, our mutant screen identified an APL (M9N) that
exhibited in increased hybridoma reactivity that also exhibited decreased peptide binding.
This is of interest because the substitution is from a tolerated (methionine) to a preferred
(asparagine) residue in the P9 anchor, which might have been expected to increase binding
stability. The peptides T6S and T6P were shown to stabilize H2Ld approximately the same
as HL10 peptide, whereas the peptides K7R and M9N stabilize H2Ld less well than the wild
type HL10 peptide. These results suggest that the screen can identify two classes of APLs,
those that affect MHC binding (H1A and H1S peptides) and since the second class does not
bind MHC as well, we would infer that the second class mutants affect the interaction of the
peptide:MHC complex with the T cell receptor (T6S, T6P, K7R, and M9N peptides).
Indeed, when these APLs (T6S, T6P, K7R) are compared to the published H2Ld motif, these
residues are predicted to be found between anchor residues and thus potentially available for
peptide:TCR interactions.
3.4. Overview and characterization of a genomic library of F. tularensis SchuS4 ORFs
The utility of the HL10 mutant collection for identifying novel altered peptide ligands led us
to speculate that this approach could be modified and applied to the identification of novel
antigen reactivities within pathogen genomes. We took advantage of a genomic library of
Francisella tularensis to test the feasibility of utilizing a defined genomic array to identify
novel targets of cellular immunity. The F. tularensis SchuS4 library encompasses the
majority of open reading frames (ORF) within a set of approximately 1800 bacterial clones
in a Gateway donor vector. For this work we used the bacterial expression vector pBAD-
DEST49, which produces a fusion protein containing the bacterial protein thioredoxin fused
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to the Francisella ORF followed by V5 and 6x His tags (Figure 5A). The Francisella entry
clone library was shifted individually into the pBAD-DEST49 expression vector and a
random selection of clones from each recombined library plate was sampled for sequence
verification for quality control purposes, as described in Materials and Methods section 2.3.
The library of pBAD-DEST49 clones, constituting the expression library, was then used for
protein production of antigens from F. tularensis strain SchuS4 (Valentino and Frelinger,
2009). Importantly, the library was acquired in a 96 well plate, arrayed format, which was
maintained throughout the production and isolation of recombinant protein. Our initital
analysis of crude lysates from the Francisella expression clones indicated that there was
significant variability in the protein expression levels (data not shown), which are likely
influenced by the characteristics of the particular Francisella ORF. This finding was in
contrast to the HL10 mutant collection where the clones exhibited almost equivalent levels
of protein expression amongst all the clones in the collection, likely due to each clone being
identical except for a single amino acid substitution. However, we reasoned that purification
of the Francisella proteins using the 6x His tag expressed on each protein could help
mitigate this variability or at least generate sufficient material to be tested. The purification
step was carried out in a high-throughput fashion aided by a semi-automated BioRobot 3000
to purify the proteins using Ni-NTA column in a 96 well plate format, as reviewed by our
lab (Valentino and Frelinger, 2009).
To verify expression and purification, individual plates from the Francisella expression
library were transferred onto nitrocellulose membranes using a 96 well dot blot apparatus
and proteins detected by antibody directed against the thioredoxin fusion partner protein (see
Figure 5A). Importantly, since the proteins were purified using the 6xHis tag located at the
carboxyl-terminus and detected with anti-thioredoxin antibodies directed at the amino-
terminus, these dot blots should detect full-length proteins. As seen in Figure 5B for a
selection of plates, Ni-NTA purification was successful in isolating approximately 75% of
recombinant proteins in our library. In general, the smaller ORFs (43–163 amino acids (aa))
were routinely expressed and purified efficiently, but interestingly, we observed a decrease
in the efficiency of protein production and purification with increasing ORF size. We
propose that this may reflect factors intrinsic to the larger ORFs, such as potential membrane
localization or hydrophobicity properties. This line of reasoning led us to speculate whether
or not the purification efficiency could be improved with the addition of detergent to the
lysis buffer. As illustrated in Figure 5C, the purification efficiency for every size range of
ORF could be improved by the simple addition of Nonidet P-40 (NP-40) detergent to the
lysis buffer. These data indicated that approximately 85% of the Francisella expression
library could be expressed and purified and was now available as a source of antigen for the
T cell hybridoma functional screenings. While the studies presented here focus on
identification of cellular reactivity, several recent studies have also indicated a role for
antibodies directed against Francisella antigens (Baron et al., 2007; Kirimanjeswara et al.,
2007; Kirimanjeswara et al., 2008; Rawool et al., 2008). The data shown in Figure 5
together with other evidence from our lab (Valentino et al., 2011) suggest that the dot blots
could also be used to interrogate the Francisella expression library for antibody reactivities
that may arise during infection or immunization.
3.5. Identification of T cell antigens within the F. tularensis SchuS4 expression library
Employing an approach conceptually similar to that used to identify APLs, the purified
recombinant-expressed Francisella proteins were individually coupled to tosyl-activated
beads and screened against Francisella specific hybridomas in a T cell functional assay.
This approach allowed for the screening of the majority of the F. tularensis strain SchuS4
proteome. In preparation for screening, we evaluated the approach using the hybridoma
FT13 1E4B4, which was previously described to recognize the Francisella lipoprotein Tul4
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(Valentino et al., 2009) and serves as a positive control when screened with the library plate
(designated plate KP) that contains its cognate protein Tul4 (also referred to as Lpn) (Figure
6A). As can be seen from Figure 6A, the FT13 1E4B4 is activated only by the single well of
the 96 well plate that contains Tul4 protein (well H2), while all other wells show low
reactivity as expected, serving as internal negative controls. The specificity and sensitivity
of the T cell functional assay supported the concept that screening the expression library
against hybridomas with unknown molecular reactivity would yield cellular reactive
antigens. Indeed, through one of our screenings, the FT25 6D10 hybridoma, generated by
infection with F. tularensis LVS, was found to be activated by the well H11 of library plate
KS, which encoded the 50S ribosomal subunit protein L3 (Figure 6B). To assess variability
and re-validate the putative reactivity of the FT25 6D10 hybridoma towards L3 protein
found during the screening (Figure 6A&B), a ‘criss-cross’ experiment was conducted
(Figure 6C). In this experiment a subset of five proteins from both plates KP and KS were
re-arrayed in a 96 well plate to include replicates and were screened against each of the
hybridomas. As expected, the Tul4 specific hybridoma FT13 1E4B4 was only activated by
the wells containing Tul4 protein (0901) (Figure 6C top). Furthermore, the FT25 6D10
specificity for L3 protein was confirmed because only the wells producing the protein L3
(0128) activated the hybridoma with minimal variability between replicates (Figure 6C
bottom). These experiments indicate that screening a proteome-wide expression library with
a T cell functional assay is a feasible approach to identify cellular targets within a complex
organism.
3.6. Mapping and validation of the epitope recognized within L3
Upon discovering cellular reactivity towards the L3 protein, it was also of interest to identify
the minimum active peptide epitope that was specifically recognized by the hybridoma. Our
laboratory has also used the T cell functional assay platform to successfully map the specific
T cell molecular determinants in defined antigens (Turner et al., 2001; Valentino et al.,
2009; Valentino et al., 2011). We have taken a similar approach to that described previously
to map the epitope within L3 recognized by the FT25 6D10 hybridoma and used carboxy-
terminal deletion constructs of L3 expressed in the pQE40 vector (Figure 7A). In this
approach, the loss of hybridoma reactivity indicates the recognized epitope is no longer
present in the construct and thus is unable to activate the hybridoma. As shown in Figure
7B, FT25 6D10 hybridoma reactivity could be mapped to the first 35 amino acids of L3
(Figure 7B). Further deletion constructs within these amino acids identified residues 1 – 19
as the minimal peptide necessary for hybridoma activation, with amino acids 1 – 22 having
the greatest stimulatory capacity (Figure 7C). Synthesized peptides containing residues 1 –
21 and 7 – 21 of L3 were shown to be fully capable for eliciting FT25 6D10 activation
(Figure 7D), indicating that these residues were indeed the epitope as presented complexed
with the I-Ad restriction element (Figure 7E). The presence of a cysteine residue was shown
to have little effect on the stimulatory capability of the epitope, such that the altered peptide
(L3 7-(C10S)-21) showed similar reactivity as the wild type peptide 7 – 21 (see Figure 7D).
The identification of a ribosomal protein subunit L3 is consistent with previously reported
results that identified ribosomal T cell determinants in other pathogens, such as
Trypanosoma cruzi (Mesri et al., 1990) and Leishmania major (Probst et al., 2001). Other
studies have described the immunogenicity of ribosomal components and ribosome-based
vaccines from various pathogens, such as Mycobacterium tuberculosis (Youmans and
Youmans, 1964b; Youmans and Youmans, 1964a; Youmans and Youmans, 1970),
Salmonella typhimurium (Venneman and Bigley, 1969; Johnson, 1972; Johnson, 1973;
Eisenstein, 1975; Hoops et al., 1976; Misfeldt and Johnson, 1976; Misfeldt and Johnson,
1977; Eisenstein and Angerman, 1978; Misfeldt and Johnson, 1978; Misfeldt and Johnson,
1979; Angerman and Eisenstein, 1980; Kita and Kashiba, 1983; Kita et al., 1983a; Kita et
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al., 1983b), Francisella tularensis (Andron and Eigelsbach, 1975) and others (reviewed in
(Gregory, 1986)). Our discovery of a T cell epitope within the Francisella ribosomal protein
L3 is therefore in agreement with several of these studies and provides further evidence
indicating that riboproteins can elicit cellular reactivity in the context of infection and
vaccination (Gregory, 1986).
3.7. Generation of a novel Gateway destination vector
As described above, we have utilized a proteome-wide expression library to screen F.
tularensis reactive hybridomas of unknown specificity to identify the antigen recognized by
their cellular reactivity. To further extend the utility of this system and as a complementary
approach we also sought to identify epitopes in a selection of specific antigens by
recombinant protein immunization. The arrayed format of the expression library enables the
selection of specific antigens for immunization. However, these proteins as expressed in the
pBAD-DEST49 vector contain the bacterial protein thioredoxin, which makes this construct
less desirable for immunization in mice, because of the potential for also generating
thioredoxin specific hybridomas, which can complicate the screening process.
Given the efficiency and utility of the Gateway system for shifting and expressing the entire
Francisella clone library, we were also interested in developing a Gateway vector that could
be used in the same manner but would also be useful for producing protein that could be
used for immunization in mice. We engineered a novel Gateway compatible vector, called
pQE40-DEST, by inserting the Gateway cassette that contains the chloramphenicol
resistance and ccdB gene flanked by attR recombination sites into the pQE40 expression
vector (Figure 8A). ORFs from an entry clone library can be shifted into this new
destination vector in a fashion similar to that described above for pBAD-DEST49. However,
the pQE40-DEST vector differs from the pBAD-DEST49 vector in several respects. The
pQE40-DEST vector is IPTG inducible and produces a fusion protein containing a 6x His
tag followed by mouse dihydrofolate reductase (DHFR) fused in frame with the Francisella
ORF (Figure 8B). The presence of DHFR affords stability and solubility to the fused ORF,
while minimizing immunoreactivity when immunizing mice with recombinant protein, by
virtue of the DHFR being a mouse protein.
As a proof of principle, we shifted and expressed a subset of the Francisella Pathogenicity
Island (FPI) genes, the intracellular growth locus (igl) ABCD operon genes, and used the
recombinant-expressed protein in immunization of mice. The genes encoded within the FPI,
including the iglABCD operon, were of particular interest because studies have shown they
are bacterial factors that are expressed in the intracellular environment (in particular, genes
found within the iglABCD operon are among those most strongly upregulated) and are
essential for phagosomal escape, intracellular replication, and the overall virulence of
Francisella (Barker and Klose, 2007; Nano and Schmerk, 2007; Wehrly et al., 2009). The
important roles of the iglABCD genes in bacterial pathogenicity subsequently make them
interesting protein targets for the anti-Francisella immune response, since the bacteria
would not be able to delete these genes without suffering a severe loss of fitness in vivo.
Proteins from these constructs were therefore expressed, purified, and injected into mice to
generate antigen specific T cells. Hybridomas generated by this approach were screened in
functional assays against anti-CD3, the IglA, IglB, IglC, and IglD proteins individually
coupled to tosylactivated beads, and an irrelevant protein control (Tul4) coupled to
tosylactivated beads. Hybridomas that were activated by anti-CD3 and only one of the four
Igl proteins, and did not react with Tul4 protein, were deemed as having the appropriate
reactivity pattern. For these in vitro reactivity screenings, we could also take advantage of
iglA, iglB, iglC, and iglD expressed using the pBAD-DEST49 vector, which contain
thioredoxin in the fusion protein. Since the mice were not immunized with thioredoxin
containing proteins, reactivity seen against these proteins during screening would indicate
Valentino et al. Page 12













that the hybridoma specifically recognizes the Igl protein and not the DHFR region.
Employing this approach, we were able to identify a panel of hybridomas that specifically
recognized either IglB or IglC protein (data not shown).
As outlined above it was of considerable interest to also define the peptide epitopes
recognized within IglB and IglC. Thus, the antigen specific hybridomas were then subjected
to mapping experiments with deletion constructs to identify the antigenic region containing
the epitope recognized by the hybridomas as thoroughly described above in the case of the
protein L3 (see Figure 7). An illustration of the hybridoma reactivity patterns for IglC and
IglB proteins are shown in Figure 8C–E. Hybridomas from C57BL/6 mice were shown to
recognize two regions in IglC, where as those identified from BALB/c mice were found to
recognize only one region in IglC. These experiments identifying the reactive regions that
likely contained the epitopes guided the synthesis of peptides, which were subsequently
validated by screening for hybridoma reactivity (Figure 9). As shown in Figure 9A, the one
set of hybridomas (VE11 & IID5) from C57BL/6 mice could be activated by the peptides
containing residues 56–70 and 60–73, but not residues 65–80, indicating that the minimal
epitope recognized by these hybridomas is most likely residues 60–70 of IglC. Another set
of IglC-specific hybridomas (VB3 & IVB7) from C57BL/6 mice that recognized a disparate
region of IglC, were activated only by the peptide encoding residues 142–157 of IglC
(Figure 9A). Perhaps not surprisingly, while reactive to the same overall region within IglC
as the hybridomas from C57BL/6 mice, the pair of hybridomas from BALB/c animals (IIIE6
& IVD4) were activated by peptides that contained amino acids 127–143 and 131–147 of
IglC and not by the residues 142–157 (see Figure 9B), indicating that BALB/c mice
recognize a slightly different epitope peptide compared to those isolated from C57BL/6
mice, most likely due to potential differences in MHC binding between these two strains of
mice. The IglB-specific hybridoma (VB10) from C57BL/6 mice was activated by all three
peptides screened, likely due to the significant overlap in amino acid residues, with the
peptide containing amino acids 475–489 of IglB eliciting the strongest reactivity (Figure
9C). As summarized in Table 1, these studies identified one peptide epitope in IglB in
C57BL/6 mice, three peptides containing two unique epitopes of IglC in C57BL/6 mice, and
two peptides containing one unique epitope of IglC in BALB/c mice.
Importantly, additional experiments beyond the scope of this report may address the
question of whether any of the IglB or IglC epitopes described here could potentially be
protective. In a study by Jia et al, immunization with Listeria monocytogenes recombinantly
expressing IglC was shown to afford significant protection in BALB/c mice against lethal
aerosol challenge with both low and high virulence strains of Francisella tularensis,
implicating a potential protective role for the protein IglC, however the T cell epitopes
recognized during infection were not determined (Jia et al., 2009). Intriguingly, we found
that immunization with recombinant IglB resulted in T cell reactivity against an epitope that
is identical to one that occurs naturally during infection with F. tularensis LVS (Valentino et
al., 2011).
4. Conclusions
In this work we have developed a functional assay to screen particulate antigens in the form
of protein conjugated to beads. Because it is a functional screen, a key element of the
process is the antigen-specific T cell hybridoma. Here, aided by genomic sequence data and
a high throughput approach, we have used this method to screen two distinct bacterial
expression libraries to demonstrate its versatility. The HL10 mutant epitope collection, made
up of 10 individual positional libraries, enabled the identification of epitopes with an
increased ability to stimulate a class I restricted T cell hybridoma. The Francisella
expression library, encompassing the majority of open reading frames of F. tularensis
Valentino et al. Page 13













SchuS4, enabled the identification and characterization of novel targets of cellular
immunity. Importantly, the spatially addressed format of both these libraries is a key feature
enabling a priori knowledge of the proteins at each location and affords the user flexibility
to select individual clones for additional analyses. Furthermore, our studies suggest this
methodology can also be modified for discovering antibody reactivities recognized during
infection or immunization. In addition, proteins from the Francisella library produced from
an expression vector newly constructed for these studies enabled the immunization of mice
with defined antigens for the identification of T cell epitopes. Ultimately, the discovery
methodologies we have developed here illustrate the feasibility of screening protein libraries
in a high-throughput approach.
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• We have developed a method to identify T cell epitopes, which are critical tools
for many modern immunologic studies
• The method utilizes bacterial expression libraries and solid-phase antigen
delivery, which we demonstrate is suitable for screening thousands of clones
• The method was used to identify altered peptide MHC class I restricted epitopes
with super-agonist activities
• We showed the feasibility of screening an extensive expression library
constructed from Francisella tularensis
• A new expression vector was constructed for immunization and used to identify
T cell epitopes in Francisella pathogenicity island encoded proteins
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Figure 1. Scheme to identify enhanced peptide ligands of PSA epitope, HL10
A) Mutations were introduced into the HL10 epitope using degenerate oligonucleotides,
which when expressed result in random amino acid substitutions. N represents any one of 4
bases; X represents any given amino acid codon. A library was generated for each position
of the peptide epitope. B) Illustration of the oligonucleotides corresponding to the epitope
region used to generate altered peptide ligand (APL) sequences. C) Sequences encoding
APL products were cloned into the pQE40 vector and transformed en mass into E. coli.
Ninety individual colonies were picked and arrayed into wells of a 96 well plate. This
procedure was conducted for each position within the sequence of the HL10 epitope to
generate the ten individual positional mutant libraries. The bacterial clones were
subsequently expressed, lysed in individual wells of 96 well plate, and individually coupled
to tosyl-activated magnetic beads that were then used as a source of antigen in the functional
assay.
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Figure 2. HL10 mutant library screens
Each clone of the 10 mutant libraries encoding variants of the HL10 epitope was screened
individually. Approximately 90 mutant clones were screened from each library. The library
designation is indicated in the upper left-hand corner of each panel, with the numbers
indicating the position of the amino acid in the peptide epitope. Individual wells (A1, A2,
A3…H12) of a 96 well plate are indicated by the marks on the horizontal axis of each panel
and each well contains lysate from a single clone. After washing, beads that had been
coupled with protein were added to cultures containing 2 × 105 PSA-H1 and 1 × 105 cells of
RAW, a H2Ld expressing macrophage cell line. After 12 hours at 37°C wells were
developed with X-Gal and scored for the number of β-galactosidase expressing hybridomas.
PSA-HI hybridoma reactivity against the wild type HL10 epitope is shown in the first well
of each panel. Altered peptide ligands that exhibit super agonist activity are identified as
having higher levels of activation compared to the wild type sequence found in the first well.
Letters above the lines within the panel indicate the amino acid substitution in the peptide.
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Figure 3. Activity of mutant synthetic peptides on the activation of PSA-HI
Synthetic peptides corresponding to the altered peptide ligands identified in the library
screens were tested for activity using the HL10 specific hybridoma PSA-HI. Decreasing
concentrations of peptides were added to 1 × 105 PSA-HI and 1 × 105 cells of RAW.
Cultures were incubated overnight at 37°C. β-galactosidase expression was measured using
CPRG. Peptides are denoted as follows: (X) HL10 (WT), (▼) F8G (a negative control), (○)
T6S, (□) T6P, (●) H1A, (■) H1S, (△) M9N, and (▲) K7R. Note: numbers indicate the
position of mutation in the peptide (e.g. T6S is a threonine to serine substitution at position 6
in the peptide).
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Figure 4. T-2 stabilization assays using the altered peptide ligands
Peptide stabilization of empty H2Ld was assessed using T2-Ld cells, as described in
materials and methods section 2.2. Briefly, the cell line T2-Ld expresses low levels of
unstable surface H2Ld on its surface {Anderson, 1993 #602}, which can be stabilized by
pulsing the cells with peptide that binds the H2Ld molecule. T2-Ld cells were incubated with
the altered HL10 epitope peptides shown for 16 hours, and were assayed for surface
stabilized H2Ld, detected using the anti-Ld antibody clone 30-5-7S. Cells were secondary
stained with goat-anti-mouse FITC and analyzed by flow cytometry. Peptide loading is
reported as the ratio of mean channel fluorescence of mutant and control peptides divided by
the mean channel fluorescence of HL10, after the subtraction of background staining from
each.
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Figure 5. Verification of protein expression from the Francisella expression library
A) Illustration of the fusion protein produced by the Gateway pBAD-DEST49 vector. The
individual Francisella ORFs were recombined into pBAD-DEST49 vector in frame to attach
the bacterial protein thioredoxin (THIO) and V5 and 6x His tags. Protein sequence resulting
from the recombination sites is denoted as attB1/attB2. Expression clones containing
Francisella ORFs were lysed either without (B) or with addition of 0.5% NP-40 (C)
detergent to the lysis buffer, prior to purification over Ni-NTA chromatography. B & C)
Protein expression and purification was verified by blotting an aliquot of each protein onto
nitrocellulose using a BioRad dot blot apparatus and probing with anti-thioredoxin antibody
followed by detection with anti-mouse IgG-HRP. A dot blot for each library expression
plate (twenty 96 well plates in total) was conducted. Dot blots of library plates
representative of ORFs ranging 43–163 aa (left), 163–362 (middle), and 362–1171 aa (right)
that encompass a range of sizes of Francisella ORFs are shown. The inclusion of 0.5%
NP-40 detergent to the lysis buffer was shown to substantially increase the purification
yield, the same selection of plates are shown for both conditions and were processed
identically.
Valentino et al. Page 24













Figure 6. Illustration of the protein library screening approach
A & B) Purified protein from each expression library plate were screened against
Francisella specific hybridomas in a functional assay and activated cells were identified and
enumerated by X-Gal. A) The Tul4 specific hybridoma FT13 1E4B4 showed reactivity to
only one well when screened against the library plate KP containing its cognate antigen
(well H2) and 95 other Francisella proteins, which serve as negative controls. B) The FT25
6D10 hybridoma of unknown specificity, shows reactivity to an antigen in the library plate
KS (well H11), while no reactivity was seen against the other 95 proteins. C) A subset of
five proteins from plates KS and KP, including the antigens recognized by the two
hybridomas, were re-arrayed to include replicates and were screened in functional assays
against the FT13 1E4B4 and FT25 6D10 hybridomas. The proteins are denoted by their FTT
designation number (eg. 0767c = FTT0767c). The control FT14 1E4B4 hybridoma was
specifically activated by FTT0128 (Tul4) located in plate KP, whereas, the FT25 6D10
hybridoma was activated by FTT0128 (L3) located in plate KS. Error bars represent
standard deviation from the mean. Representative reactivity patterns from two experiments
are shown.
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Figure 7. Mapping and validating the epitope reactivity of the FT25 6D10 hybridoma
Hybridomas were incubated with splenocytes and deletion proteins conjugated to tosyl-
activated beads. A) Illustration of full length L3 and the four carboxy-terminal deletion
constructs in the pQE40 bacterial expression vector, the black box indicates 6x His tag, the
gray box indicates murine DHFR protein, and the open box denotes the portions of L3
protein fused in frame with DHFR. B) The constructs shown in (A) were used for initial
mapping experiments. C) Fine mapping experiments indicate the hybridoma recognized an
epitope within the first 21 amino acids of L3. D) Synthesized peptides were used to validate
the hybridoma recognized an epitope within residues 7–21 of L3. E) The M12 B cell line
expressing only either I-Ed or I-Ad indicated that the hybridoma recognizes the L3 1–21
peptide displayed by the I-Ad restriction element.
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Figure 8. A new Gateway vector was utilized to generate IglC and IglB specific hybridomas for
epitope mapping studies
A) A schematic of the newly constructed destination vector pQE40-DEST. The Gateway
cassette was inserted into the multiple cloning site of pQE40 vector to generate the pQE40-
DEST vector. Chloramphenicol resistance gene (CmR), ccdB suicide gene (ccdB), and
recombination sites (attR1/attR2) are denoted. B) Illustration of the fusion protein
containing a Francisella ORF expressed by the pQE40-DEST vector. C & D) Summary of
IglC hybridoma reactivity in C57BL/6 (C) and BALB/c (D) mice. E) Summary of IglB
hybridoma reactivity in C57BL/6 mice. The individual carboxy-terminal truncation deletion
constructs for each protein are indicated by amino acid numbers within each protein. Protein
specific hybridomas are indicated (a) above their respective reactivity regions (b, c) which
were determined using the deletion constructs. T cell hybridomas that were utilized for
further validation with peptides are denoted with boxes. The peptides that were subsequently
synthesized are also shown and indicated by black bars.
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Figure 9. Validation of IglC and IglB epitopes using synthetic peptides
A) The IglC specific hybridomas from C57BL/6 mice recognized two different epitope
regions within IglC and were activated by peptides 56–70 and 60–73 or 142–157. B) The
IglC specific hybridomas from BALB/c mice recognized a single epitope region within IglC
and were activated by peptides 127–143 and 131–143. C) The IglB specific hybridoma from
C57BL/6 mice recognizes a single epitope region within IglB and was activated by the
overlapping peptides 472–486, 475–486, and 475–489.
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Table 1
Summary of epitopes identified by recombinant protein immunization of selected Francisella ORFs expressed
in the pQE40-DEST vector
Protein Mouse strain AA residues Epitope sequence
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